Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: Through anti-fibrotic and anti-oxidative stress pathways

Biomedical Research (Japan)

Volumn 34, Issue 6, 2013, Pages 309-319

  Ji, Xu ^a,b   Naito, Yukiko ^b   Weng, Huachun ^b   Ma, Xiao ^b   Endo, Kosuke ^b   Kito, Naoko ^b   Yanagawa, Nariaki ^b   Yu, Yang ^a   Li, Jie ^a   Iwai, Naoharu ^b  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; GELATINASE B; INTERLEUKIN 1BETA; PIRFENIDONE; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDATIVE STRESS ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; HISTOPATHOLOGY; INTERLEUKIN 1BETA BLOOD LEVEL; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CATALASE; FIBROSIS; GENE EXPRESSION REGULATION; HYPERTENSION, RENAL; KIDNEY; MALE; MATRIX METALLOPROTEINASE 9; OXIDATIVE STRESS; PROTEINURIA; PYRIDONES; RATS; RATS, INBRED DAHL; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SODIUM CHLORIDE, DIETARY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891072491     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.34.309     Document Type: Article

References (39)

1. Al-Bayati MA, Xie Y, Mohr FC, Margolin SB and Giri SN (2002) Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem pharm 64, 517-525.
2. Arumugam TV, Shiels IA, Margolin SB, Taylor SM and Brown L (2002) Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine. Clin Exp Pharmacol physiol 29, 996-1000.
3. Border WA, Okuda S, Languino LR, Sporn MB and Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346, 371-374.
4. Bottinger EP and Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13, 2600-2610.
5. Brook NR, Waller JR, Bicknell GR and Nicholson ML (2005) The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 125, 137-143.
6. Brook NR, Waller JR, Bicknell GR and Nicholson ML (2005) The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc 37, 130-133.
7. Cho ME, Smith DC, Branton MH, Penzak SR and Kopp JB (2007) Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2, 906-913.
8. Chromek M, Tullus K, Hertting O, Jaremko G, Khalil A, Li YH and Brauner A (2003) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res 53, 698-705.
9. Derynck R and Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584.
10. Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L and Benedetti A (2004) The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36, 744-751.
11. Gonzalez-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C and Montano M (1998) Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology 66, 196-204.
12. Grattendick KJ, Nakashima JM, Feng L, Giri SN and Margolin SB (2008) Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int immunopharmacol 8, 679-687.
13. Hale ML, Margolin SB, Krakauer T, Roy CJ and Stiles BG (2002) Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 70, 2989-2994.
14. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB and Becker GJ (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14, 453-460.
15. Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R and Iwai N (2012) P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 35, 173-179.
16. Ji X, Naito Y, Weng H, Endo K, Ma X and Iwai N (2012) P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate (DOCA)-salt hypertension. Am J Physiol 308, F1207-2015.
17. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y and Iwai N (2009) Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 55, 1944-1949.
18. Jin Y, Ratnam K, Chuang PY, Fan Y, Zhong Y, Dai Y, Mazloom AR, Chen EY, D'Agati V, Xiong H, Ross MJ, Chen N, Ma'ayan A and He JC (2012) A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 18, 580-588.
19. Kobayashi M, Sugiyama H, Wang DH, Toda N, Maeshima Y, Yamasaki Y, Masuoka N, Yamada M, Kira S and Makino H (2005) Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int 68, 1018-1031.
20. Lee KW, Everett THt, Rahmutula D, Guerra JM, Wilson E, Ding C and Olgin JE (2006) Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114, 1703-1712.
21. Lelongt B, Bengatta S, Delauche M, Lund LR, Werb Z and Ronco PM (2001) Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med 193, 793-802.
22. Ludwig S, Engel K, Hoffmeyer A, Sithanandam G, Neufeld B, Palm D, Gaestel M and Rapp UR (1996) 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol 16, 6687-6697.
23. McMillan JI, Riordan JW, Couser WG, Pollock AS and Lovett DH (1996) Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 97, 1094-1101.
24. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM and Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133, 687-694.
25. Mo W, Brecklin C, Garber SL, Song RH, Pegoraro AA, Au J, Arruda JA, Dunea G and Singh AK (1999) Changes in collagenases and TGF-beta precede structural alterations in a model of chronic renal fibrosis. Kidney Int 56, 145-153.
26. Piek E, Moustakas A, Kurisaki A, Heldin CH and ten Dijke P (1999) TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112 (Pt 24), 4557-4568.
27. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA and Sharma K (2009) Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 20, 1765-1775.
28. Reddi AS and Bollineni JS (2001) Selenium-deficient diet induces renal oxidative stress and injury via TGF-beta1 in normal and diabetic rats. Kidney Int 59, 1342-1353.
29. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J and Johnson RJ (2001) Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59, 1626-1640.
30. Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, Castrejon-Gomez E and Armendariz-Borunda J (2008) Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 595, 69-77.
31. Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts IS, Mundel P and Bottinger EP (2002) Inhibitory Smads and TGF-Beta signaling in glomerular cells. J Am Soc Nephrol 13, 2657-2666.
32. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC and Kopp JB (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22, 1144-1151.
33. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB and Weisberg LS (1997) Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854-859.
34. Shihab FS, Bennett WM, Yi H and Andoh TF (2002) Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2, 111-119.
35. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F and Kurokawa K (1997) Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63, S239-243.
36. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB and Kurokawa K (1998) Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54, 99-109.
37. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE and Neilson EG (1995) Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130, 393-405.
38. Takakuta K, Fujimori A, Chikanishi T, Tanokura A, Iwatsuki Y, Yamamoto M, Nakajima H, Okada M and Itoh H (2009) Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 629, 118-124.
39. Wang S, Wilkes MC, Leof EB and Hirschberg R (2005) Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19, 1-11.